{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:10:37Z","timestamp":1795011037951,"version":"4.9.1"},"reference-count":51,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Public Hospital of Marseille (Assistance Publique des H\u00f4pitaux de Marseille)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Immune checkpoint inhibitors (ICIs) are a major breakthrough in cancer treatment. Their increasingly frequent use leads to an uprising incidence of immune-related adverse events (irAEs). Among those, myocarditis is the most reported fatal cardiovascular irAE, frequently associated with ICI-related myositis. Case series: Here, we report three cases of ICI-induced myocarditis\/myositis with an extremely severe myasthenia gravis-like (MG-like) presentation, highlighting the main challenges in irAEs management. These patients were over 60 years old and presented an ongoing melanoma, either locally advanced or metastatic, treated with ICI combinations. Shortly after the first or second ICI infusion, they were admitted in an intensive care unit (ICU) for grade 3 ICI-induced MG-like symptoms leading to acute respiratory failure (ARF) requiring invasive mechanical ventilation (IMV). The initial misdiagnosis was later corrected to severe ICI-induced seronegative myocarditis\/myositis upon biological results and histopathology from muscular\/endomyocardial biopsies. All of them received urgent high-dose corticosteroids pulses. The oldest patient died prematurely, but the two others received targeted therapies leading to complete recovery for one of them. Discussion: These cases highlight the four main challenges of irAEs, encompassing the lack of knowledge among physicians, the risk of misdiagnosis due to numerous and non-specific symptoms, the frequent overlapping forms of irAEs, and the extremely rare MG-like misleading presentation of myocarditis\/myositis. The exact pathophysiology of irAEs remains unclear, although a major involvement of the lymphoid compartment (specifically T lymphocytes) was evidenced. Therapeutic management is based on urgent high-dose corticosteroids. For the severest forms of irAEs, case-by-case targeted immunosuppressive therapies should be urgently administered upon multidisciplinary meetings. Conclusion: These cases highlight the lack of knowledge of irAEs among physicians, aggravated by misleading overlapping forms, requiring specific management in trained units and multidisciplinary care. Severe MG-like presentation of irAEs constitutes an absolute therapeutic emergency with high-dose corticosteroids and targeted immunosuppressive therapy.<\/jats:p>","DOI":"10.3390\/jcm11195611","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T01:41:58Z","timestamp":1664156518000},"page":"5611","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immune Checkpoint Inhibitor-Induced Myositis\/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit"],"prefix":"10.3390","volume":"11","author":[{"given":"Fran\u00e7ois","family":"Deharo","sequence":"first","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Carvelli","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-8191","authenticated-orcid":false,"given":"Jennifer","family":"Cautela","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Garcia","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sarles","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Maues de Paula","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Bourenne","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gainnier","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Bichon","sequence":"additional","affiliation":[{"name":"Marseille Public University Hospital System, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"(2022). FDA approves anti-LAG3 checkpoint. Nat. Biotechnol., 40, 625.","DOI":"10.1038\/s41587-022-01331-0"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Brahmer","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis with Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","article-title":"Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data","volume":"11","author":"Makunts","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_16","first-page":"292","article-title":"Myocarditis with Immune Checkpoint Blockade","volume":"376","author":"Moslehi","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13613-020-00761-w","article-title":"Immune-related adverse events: A retrospective look into the future of oncology in the intensive care unit","volume":"10","author":"Joseph","year":"2020","journal-title":"Ann. Intensive Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","article-title":"New therapeutic perspectives to manage refractory immune checkpoint-related toxicities","volume":"20","author":"Martins","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41571-020-0400-4","article-title":"Personalized treatment of immune-related adverse events\u2014Balance is required","volume":"17","author":"Martins","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Crudele, L., Leone, P., Argentiero, A., Guarascio, M., Silvestris, N., Vacca, A., and Racanelli, V. (2020). Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093054"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.accpm.2018.10.013","article-title":"French legal approach to clinical research","volume":"37","author":"Toulouse","year":"2018","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15567","DOI":"10.1038\/s41598-020-72649-5","article-title":"Landscape of immune checkpoint inhibitor-related adverse events in Chinese population","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/onco.13931","article-title":"Immune Checkpoint Inhibitor\u2013Induced Myocarditis with Myositis\/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-Related Adverse Events: A Case-Based Approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e001935","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: Study of a population level insurance claims database from the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s00262-021-02996-3","article-title":"Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: A systematic review and meta-analysis","volume":"70","author":"Bokern","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data","volume":"17","author":"Shimozaki","year":"2021","journal-title":"Future Oncol."},{"key":"ref_38","unstructured":"Sullivan, R.J., and Weber, J.S. (2021). Immune-Related Toxicities of Checkpoint Inhibitors: Mechanisms and Mitigation Strategies. Nat. Rev. Drug Discov., Available online: http:\/\/www.nature.com\/articles\/s41573-021-00259-5."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis","volume":"66","author":"Khan","year":"2020","journal-title":"Clin. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor\u2013Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non\u2013Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Masuda, K., Shoji, H., Nagashima, K., Yamamoto, S., Ishikawa, M., Imazeki, H., Aoki, M., Miyamoto, T., Hirano, H., and Honma, Y. (2019). Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6150-y"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1200\/JCO.18.02464","article-title":"Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely","volume":"37","author":"Spallarossa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5611\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:38:27Z","timestamp":1760143107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":51,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195611"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195611","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}